Keyphrases
Infiltration
100%
Autopsy
100%
Monocytic
100%
Alemtuzumab
100%
Neuromyelitis Optica
100%
Clinical Relapse
37%
Contrast-enhancing Lesions
37%
Lymphocytes
25%
Fluid-attenuated Inversion Recovery (FLAIR)
25%
Hyperintensity
25%
Innate Immune Response
12%
Immunosuppressive Therapy
12%
Paucity
12%
Brainstem
12%
Adaptive Immunity
12%
Clinical Course
12%
Neuropathology
12%
Tissue Injury
12%
Multiple Sclerosis
12%
Older Women
12%
Nausea-vomiting
12%
Vision Loss
12%
Progressive multiple Sclerosis
12%
Demyelinating Lesions
12%
Non-enhancing
12%
Brain MRI
12%
Tissue Destruction
12%
Disability Progression
12%
Macrophage Infiltration
12%
Aquaporin-4 (AQP4)
12%
Spinal Cord MRI
12%
Immunology and Microbiology
Alemtuzumab
100%
Neuromyelitis Optica
100%
Magnetic Resonance Imaging
37%
Lymphocyte
25%
Macrophage
12%
Immunoglobulin G Antibody
12%
Adaptive Immune System
12%
Spinal Cord
12%
Multiple Sclerosis
12%
Brain Stem
12%
Immunosuppressive Therapy
12%
Aquaporin
12%
Secondary Progressive Multiple Sclerosis
12%
Neuroscience
Neuromyelitis Optica
100%
Alemtuzumab
100%
Magnetic Resonance Imaging
25%
Lymphocyte
25%
Immunosuppressive Drug
12%
Macrophage
12%
Multiple Sclerosis
12%
Brainstem
12%
Magnetic Resonance Imaging of Brain
12%
Immunoglobulin G Antibody
12%
Aquaporin 4
12%
Secondary Progressive Multiple Sclerosis
12%
Acquired Immunity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Alemtuzumab
100%
Myelooptic Neuropathy
100%
Multiple Sclerosis
25%
Immunosuppressive Agent
12%
Tissue Injury
12%
Disease Course
12%
Visual Impairment
12%
Nausea and Vomiting
12%
Aquaporin 4
12%
Immunoglobulin G Antibody
12%